Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000726436 | SCV000344634 | uncertain significance | not provided | 2016-08-09 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000346646 | SCV000724415 | likely benign | not specified | 2018-01-26 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Ambry Genetics | RCV000621443 | SCV000735791 | likely benign | Cardiovascular phenotype | 2017-03-02 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV001087114 | SCV001007286 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2024-01-16 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000726436 | SCV005042214 | likely benign | not provided | 2024-04-01 | criteria provided, single submitter | clinical testing | JAG1: BP4, BP7 |
Prevention |
RCV004549621 | SCV004777767 | likely benign | JAG1-related disorder | 2021-05-04 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |